Hologic — Q2 2023 Earnings Presentation
38 slides from Hologic's earnings presentation, May 2023
Slide 1: Purpose Driven. Results Driven.
Purpose Driven. Results Driven. May 2023 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or other
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this presentation: constant currency revenues; organic revenues; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAA
Slide 4: Presentation Outline
Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 4
Slide 5: Investment Thesis
Investment Thesis • Purpose Driven, Results Driven • Commitment to purpose supercharges engagement and amplifies strength • Transformation into a much stronger Company than pre-pandemic ○ More diverse, recurring revenue ○ More long-term growth opportunities ○ More global ○ With stronger base busines
Slide 6: Presentation Outline
Presentation Outline Introduction Purpose Driven Results Driven Conclusion 6
Slide 7: An Unparalleled Commitment to Women's Health
An Unparalleled Commitment to Women's Health 7
Slide 8: ESG Focus: Making a Unique Difference in the World
ESG Focus: Making a Unique Difference in the World • Strong financial results enable us to live into our Purpose, Passion and Promise more fully than ever before • Driving meaningful change with the Hologic Global Women’s Health Index, Project Health Equality and our Global Access Initiative • Focus
Slide 9: Our Purpose Creates A Unique Strength
Our Purpose Creates A Unique Strength Together, we achieve MORE! 9
Slide 10: Elevating Global Women's Health…
Elevating Global Women's Health… …Through important social initiatives including: Hologic Global Women’s Health Index Project Health Equality Global Access Initiative 10
Slide 11: Elevating Hologic's Company Profile…
Elevating Hologic’s Company Profile… …By engaging world leaders, scoring big at the Super Bowl and partnering with the WTA — a global effort with global reach World Economic Forum Mary J. Blige & the Super Bowl Women’s Tennis Association 11
Slide 12: Culture Creates Competitive Advantage
Culture Creates Competitive Advantage Purpose + Results = World Class Engagement Engagement underpins our recognition as a highly Purpose underpins exceptional engagement ranked Top Workplace Stellar Engagement per Gallup Q12 Survey 2022 recognition as a Top Workplace at two of our largest employee
Slide 13: Presentation Outline
Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 13
Slide 14: Hologic Overview
Hologic Overview • Revenue of $4,863 million in fiscal 2022 By Division By Type By Geography Surgical Service 11% and Other 14% INTL 29% Capital 12% Breast and Diagnostics Skeletal 62% Consumables US 27% 74% 71% Note: Percentages in pie charts are for FY22. 14
Slide 15: Strong Fiscal 2022 with Base Businesses Poised to Drive Growth…
Strong Fiscal 2022 with Base Businesses Poised to Drive Growth… Total Revenue* 46.5% $6,000 $5,632 -12.3% $5,000 $4,863 12.1% $2,160 $4,000 5.7% $3,776 $1,431 8.3% 4.3% $3,218 $3,367 $3,059 $929 $3,000 9.9% 5.4% 0.4% $2,000 ** $1,000 $2,511 $2,705 $2,833 $2,851 $2,879 $3,052 $2,782 $3,473 $3,433 $0
Slide 16: …And Deliver Robust Profitability
…And Deliver Robust Profitability Non-GAAP EPS* $9.00 111.3% $8.00 $7.00 -28.4%** $6.00 $5.00 63.8% $4.00 $3.00 9.0% 3.6% 9.9% 17.4% $2.00 -2.7% 14.4% $1.00 $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02 $0.00 2014 2015 2016 2017 2018 2019 2020 2021 2022 *Non-GAAP EPS as presented in our earn
Slide 17: Generated $5 Billion in FCF over the Past 3 Years
Generated $5 Billion in FCF over the Past 3 Years More than $3 Billion Deployed Since FY’20 M&A Accelerates Growth • Redeployed FCF* to drive growth across • 6 deals across each division the board ○ Diagnostics • Over $1.4 billion on M&A** – Biotheranostics, Diagenode, Mobidiag ○ Breast Health • Ove
Slide 18: Strong Q2 2023 Results
Strong Q2 2023 Results Q2’22 Q2’23 Revenue Change (CC) Revenue Diagnostics $464.7 $987.1 (52.2%) Organic Diagnostics $355.0 $314.2 14.9% excluding COVID Organic Molecular Diagnostics excluding $243.1 $198.8 23.9% COVID Breast Health $385.4 $310.4 25.7% GYN Surgical $144.8 $117.3 25.2% Skeletal Healt
Slide 19: Diagnostics Powered by Molecular…
Diagnostics Powered by Molecular… Global Diagnostics* Revenue • Molecular Diagnostics drives Growth: + LDD Growth ○ +3,250 Panther instruments globally $1,321 ○ Menu adoption and utilization drive $1,029 long-term growth Upside from COVID testing $846 Millions ○ $557 • Steadfast leadership in Cytolo
Slide 20: …With Improving Utilization Post-COVID…
…With Improving Utilization Post-COVID… • Panther non-COVID utilization gaining traction* • Existing and new customers adding contracted non-COVID menu ○ ~ 85% of all New Customers** running at least one other assay in addition to COVID ○ ~ 55% of all New Customers** running at least two other assay
Slide 21: …And a Broad Menu with More on the Way
…And a Broad Menu with More on the Way FDA Approved Assays on Panther* • Menu in development for FDA 19 approval: ○ SARS-CoV-2/Flu/A/B/RSV ○ GI ○ GBS ○ EBV and BKV ○ C. Difficile 4 ○ M. gen resistance ○ Chlamydia trachomatis 2014 2022 ○ Neisseria gonorrhoeae * Includes both Panther and Panther Fusio
Slide 22: Breast Health Recovery Through 2023…
Breast Health Recovery Through 2023… • A more diverse and recurring business Breast Health Revenue $1,400 • 2023 recovery in Mammography $1,200 ○ Breast Health constant currency revenue up $1,000 45% 25.7% in Q2’23 $800 38% • Interventional and International drive growth $600 17% 25% $400 • IMV Serv
Slide 23: …with Leadership Across the Continuum of Care
…with Leadership Across the Continuum of Care ARTIFICIAL INTELLIGENCE & ANALYTICS 23
Slide 24: Robust Surgical Growth Continues
Robust Surgical Growth Continues Global Surgical* Revenue • Stability in NovaSure +LDD Growth $522 • Continued strength in core MyoSure $437 • Underappreciated contribution from Fluent Fluid Management Millions • Strong growth in Laparoscopic portfolio: Acessa and Bolder • 25.2% constant currency or
Slide 25: Strong Balance Sheet for Future Capital Deployment Opportunities
Strong Balance Sheet for Future Capital Deployment Opportunities • Leverage well under 1x provides Net Debt and Leverage Ratio* $4.0 firepower for internal investment, M&A, $4.0 $3.5 share repurchases 4.6x $3.1 $3.0 4.0x $2.8 $2.8 • No near-term debt maturities, $2.6 $2.5 3.3x 2.8x $2.3 no balance o
Slide 26: Presentation Outline
Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 26
Slide 27: Investment Thesis
Investment Thesis • Purpose Driven, Results Driven • Commitment to purpose supercharges engagement and amplifies strength • Transformation into a much stronger Company than pre-pandemic ○ More diverse, recurring revenue ○ More long-term growth opportunities ○ More global ○ With stronger base busines
Slide 28: Financial Overview Q2'23
Financial Overview Q2’23 Non-GAAP $M, except EPS Q2’23 ∆ vs. Q2’22 Revenue $1,026.5 (28.5%) and (27.5%) CC Organic $1,015.9 (28.8%) and (27.7%) CC Organic ex COVID $916.8 20.2% and 21.9% CC Gross Margin 62.1% (890 bps) Operating Expenses $317.0 (6.3%) Operating Margin 31.3% (1,610 bps) Net Margin 25
Slide 29: Updated 2023 & Q3'23 Financial Guidance
Updated 2023 & Q3’23 Financial Guidance Full Year* Q3’23* 2023 Guidance Q3’23 Guidance Revenue $3,925 – $4,025 $930 – $980 GAAP Diluted EPS $2.91 – $3.11 $0.64 – $0.74 Non-GAAP Diluted EPS $3.75 – $3.95 $0.83 – $0.93 Prior Full Year 2023 Guidance*: Revenue: $3,850 - $4,000 GAAP Diluted EPS: $2.69 -
Slide 30: Appendix
Appendix HOLOGIC' |
Slide 31: COVID Assay and COVID Related Revenue
COVID Assay and COVID Related Revenue COVID Assay and COVID Related Revenue* $900 $823 $800 $78 $760 $664 $80 $700 $661 $63 $596 $77 $600 $514 $73 $500 $71 $400 $365 $352 $745 $41 $680 $61 $300 $601 $584 $523 $215 $443 $187 $163 $200 $42 $324 $36 $291 $36 $98 $100 $173 $151 $27 $23 $27 $127 $71 $0 1
Slide 32: Non-COVID Panther Utilization Metrics
Non-COVID Panther Utilization Metrics • Panther non-COVID utilization gaining traction: ○ + 90% of all customers running at least one other assay in addition to COVID ○ ~ 85% of all New Customers* running at least one other assay in addition to COVID ○ ~ 55% of all New Customers* running at least tw
Slide 33: Capitalization as of Q2'23
Capitalization as of Q2’23 Tranche Amount Leverage Coupon Rating Call Date Maturity Cash & Equivalents 2,582 Revolving Facility ($2,000 million) - SOFR + 110 Baa3 / BBB- 09/25/26 Term Loan 1,493 SOFR + 110 Baa3 / BBB- 09/25/26 Total Secured Debt 1,493 1.1x Senior Unsecured Notes - 2028 400 4.625% Ba
Slide 34: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended April 1, 2023 March 26, 2022 GROSS PROFIT GAAP gross profit $585.8 $946.6 Adjustments: Amortization of acquired intangible assets 52.1 72.3 Non-GAAP gross profit $637.9 $1,018.9 GROSS MARGIN P
Slide 35: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended April 1, 2023 March 26, 2022 OPERATING MARGIN GAAP income from operations $272.1 $594.1 Adjustments to gross profit as detailed above 52.1 72.3 Adjustments to operating expenses as detailed ab
Slide 36: Reconciliation of GAAP to Non-GAAP EPS Guidance
Reconciliation of GAAP to Non-GAAP EPS Guidance Guidance Range Quarter Ending July 1, 2023 Year Ending September 30, 2023 Low High Low High GAAP Net Income Per Share $0.64 $0.74 $2.91 $3.11 Amortization of acquired intangible assets $0.23 $0.23 $0.96 $0.96 Restructuring, Integration and Other charge
Slide 37: Definitions
Definitions • Organic Revenue: Total constant currency revenue excluding the divested Blood Screening business and revenue from acquired businesses owned by Hologic for less than one year. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the ac
Slide 38: For More Information
For More Information: Ryan Simon Francis Pruell VP, Investor Relations Senior Director, Investor Relations [email protected] [email protected] 38